Reviewing Adverum Biotechnologies Inc. (ADVM)’s and Agenus Inc. (NASDAQ:AGEN)’s results

Adverum Biotechnologies Inc. (NASDAQ:ADVM) and Agenus Inc. (NASDAQ:AGEN), both competing one another are Biotechnology companies. We will compare their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Adverum Biotechnologies Inc. 8 0.00 36.69M -1.12 0.00
Agenus Inc. 3 0.00 95.73M -0.80 0.00

We can see in table 1 the earnings per share, gross revenue and valuation of Adverum Biotechnologies Inc. and Agenus Inc.

Profitability

Table 2 provides us Adverum Biotechnologies Inc. and Agenus Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Adverum Biotechnologies Inc. 431,647,058.82% -33.4% -30.8%
Agenus Inc. 2,852,757,993.86% 65.6% -54.1%

Risk and Volatility

Adverum Biotechnologies Inc. is 143.00% more volatile than Standard & Poor’s 500 because the stock has a beta of 2.43. Competitively, Agenus Inc.’s beta is 1.81 which is 81.00% more volatile than Standard & Poor’s 500.

Liquidity

The Current Ratio and a Quick Ratio of Adverum Biotechnologies Inc. are 18.2 and 18.2. Competitively, Agenus Inc. has 1.7 and 1.7 for Current and Quick Ratio. Adverum Biotechnologies Inc.’s better ability to pay short and long-term obligations than Agenus Inc.

Analyst Ratings

The table given features the ratings and recommendations for Adverum Biotechnologies Inc. and Agenus Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Adverum Biotechnologies Inc. 0 1 0 2.00
Agenus Inc. 0 0 1 3.00

Adverum Biotechnologies Inc. has a consensus target price of $8, and a -25.99% downside potential. Agenus Inc. on the other hand boasts of a $6 consensus target price and a 49.63% potential upside. The results from earlier shows that analysts opinion suggest that Agenus Inc. seems more appealing than Adverum Biotechnologies Inc.

Institutional and Insider Ownership

Institutional investors held 76% of Adverum Biotechnologies Inc. shares and 33.6% of Agenus Inc. shares. Insiders held 11.22% of Adverum Biotechnologies Inc. shares. On the other hand, insiders held about 24.18% of Agenus Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Adverum Biotechnologies Inc. -8.28% 15.9% 106.94% 342.57% 185.32% 325.71%
Agenus Inc. 0.42% -18.03% -4.74% -30.75% 29.57% 1.26%

For the past year Adverum Biotechnologies Inc. was more bullish than Agenus Inc.

Summary

Agenus Inc. beats on 7 of the 11 factors Adverum Biotechnologies Inc.

Adverum Biotechnologies, Inc., a gene therapy company, discovers and develops novel medicines for patients suffering from rare diseases or diseases of eye. The company has a pipeline that includes product candidates to treat wet age-related macular degeneration (wAMD), alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. Its lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development of new anti-VEGF gene therapy candidates for wAMD diseases; and ADVM-043, which is in patient enrollment in a phase 1/2 trial for the treatment of A1AT. The company is also developing ADVM-053 to treat hereditary angioedema; and other product candidates, such as ocular therapeutics, including AVA-311 for the treatment of juvenile X-linked retinoschisis. It has collaboration agreements with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products for ophthalmic diseases; and Editas Medicine, Inc. to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the bodyÂ’s immune system for patients suffering with cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, and LAG-3. In addition, the company develops vaccine programs, such as Prophage cancer vaccine candidate; AutoSynVax, a synthetic cancer vaccine program targeting the neo-epitope landscape in cancer patients; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a novel class of tumor specific neo-epitopes. Further, Agenus Inc. develops QS-21 Stimulon, a saponin-based vaccine adjuvant that has completed Phase III clinical trials for the treatment of malaria and shingles. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.